A new way to address missing data in late-stage clinical trials.

IF 2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Jitendra Ganju, Ron Yu
{"title":"A new way to address missing data in late-stage clinical trials.","authors":"Jitendra Ganju, Ron Yu","doi":"10.1016/j.cct.2024.107750","DOIUrl":null,"url":null,"abstract":"<p><p>According to ICH E9(R1), defining the estimand comes before defining the analysis approach, and the strategies for addressing intercurrent events are key components of the estimand. With the composite strategy, the problem of missing data disappears, because it becomes part of the endpoint definition. It is this perspective that we adopt in addressing the problem of missing data. We propose comparing patients in a pairwise manner to determine which patient fared better, one patient from each group, taking into account the reason for and timing of missingness. For purposes of illustration, reasons for missingness are placed into three categories: (1) death or adverse events, (2) administration of rescue medication (treated as missing even if patient continues in the study, or a poor score is assigned), and (3) other reasons such as loss to follow-up or withdrawal of consent. Each pair of patients is compared on the endpoint of interest. The comparison outcomes are determined based on the presence of missing data, its category, and timing. For instance, if both patients in a pair have received rescue medication, the patient with the later time of rescue medication is considered to have fared better. The overall treatment effect is combined across all pairwise comparisons. This method allows the reason and timing of missing data to contribute to the assessment of treatment effects, providing a solution to some limitations of existing methods. Thus, the pairwise comparison approach addresses the missing data problem transparently via the composite strategy.</p>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":" ","pages":"107750"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cct.2024.107750","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

According to ICH E9(R1), defining the estimand comes before defining the analysis approach, and the strategies for addressing intercurrent events are key components of the estimand. With the composite strategy, the problem of missing data disappears, because it becomes part of the endpoint definition. It is this perspective that we adopt in addressing the problem of missing data. We propose comparing patients in a pairwise manner to determine which patient fared better, one patient from each group, taking into account the reason for and timing of missingness. For purposes of illustration, reasons for missingness are placed into three categories: (1) death or adverse events, (2) administration of rescue medication (treated as missing even if patient continues in the study, or a poor score is assigned), and (3) other reasons such as loss to follow-up or withdrawal of consent. Each pair of patients is compared on the endpoint of interest. The comparison outcomes are determined based on the presence of missing data, its category, and timing. For instance, if both patients in a pair have received rescue medication, the patient with the later time of rescue medication is considered to have fared better. The overall treatment effect is combined across all pairwise comparisons. This method allows the reason and timing of missing data to contribute to the assessment of treatment effects, providing a solution to some limitations of existing methods. Thus, the pairwise comparison approach addresses the missing data problem transparently via the composite strategy.

解决后期临床试验数据缺失问题的新方法。
根据 ICH E9(R1),在确定分析方法之前,首先要确定估计指标,而处理并发症的策略是估计指标的关键组成部分。有了复合策略,缺失数据的问题就不复存在,因为它已成为终点定义的一部分。我们正是从这个角度来解决数据缺失问题的。我们建议对患者进行配对比较,以确定哪位患者的情况更好,每组一名患者,同时考虑缺失的原因和时间。为了便于说明,我们将缺失原因分为三类:(1) 死亡或不良事件;(2) 施用抢救药物(即使患者继续接受研究,或评分较差,也视为缺失);(3) 其他原因,如失去随访或撤回同意。对每对患者进行相关终点的比较。比较结果根据是否存在缺失数据、缺失数据的类别和时间来确定。例如,如果一对患者中的两名患者都接受了抢救药物治疗,则认为接受抢救药物治疗时间较晚的患者情况较好。所有配对比较的总体治疗效果合并计算。这种方法允许缺失数据的原因和时间有助于评估治疗效果,解决了现有方法的一些局限性。因此,配对比较法通过综合策略透明地解决了数据缺失问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.50%
发文量
281
审稿时长
44 days
期刊介绍: Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信